Your session is about to expire
← Back to Search
ATH-1017 for Alzheimer's Disease
Study Summary
This trial is testing the safety and tolerability of fosgonimeton in Alzheimer's patients who have completed other studies.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 trial • 77 Patients • NCT04491006Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am a male and will use double contraception during and after the study.I have been newly diagnosed with severe depression without psychosis.I can sign the consent form myself or have someone legally allowed to do it for me.You experience strong and fixed false beliefs or see or hear things that are not really there.I have a newly-diagnosed cancer, but skin or early prostate cancer that's under control doesn't count.You have a high risk of attempting to harm yourself.
- Group 1: Treatment
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are new participants being admitted to this research endeavor?
"The clinical trial posted on June 30th, 2021 is no longer accepting patients. The last update was made February 28th, 2022. However, over 500 other trials are actively recruiting participants currently."
What potential risks do patients face when taking ATH-1017?
"The safety rating of ATH-1017 was assigned a 2, as the Phase 2 trial has provided data attesting to its security but no evidence proving efficacy."
Does this clinical experiment accept participants aged 20 and above?
"As per the terms of this research program, applicants must be between 55 and 85 years old to qualify for inclusion."
At what number of locations is this trial currently being conducted?
"In addition to the 3 sites previously mentioned, there are 28 other institutions offering this trial; some of these include Indiana University's Neuroscience Center and Mile High Research Center in Denver."
Who meets the eligibility criteria to participate in this investigation?
"This research programme seeks 300 individuals with Alzheimer's disease aged between 55-85. Those that meet these criteria are eligible to apply for the clinical trial."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger